Screener Summaries Updates Institutions Sign In More Updates › Other Events › IONS Other Events · Jul 9, 2026
Ionis Pharmaceuticals, Inc. is reaffirming its previously announced financial guidance for the fiscal year ending… IONS Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals, Inc. is reaffirming its previously announced financial guidance for the fiscal year ending December 31, 2026, which remains unchanged from the guidance provided on April 29, 026. Ionis Pharmaceuticals, Inc. operates in the biotechnology industry and develops medicines for human therapeutics.
More from Ionis Pharmaceuticals Inc Roche reports sefaxersen achieved a 43.1% reduction in proteinuria in Phase 3 IgAN study Oct 23, 2026 FDA approves GSK's Hibsago for chronic hepatitis B, unlocking up to 12% royalties for Ionis Oct 21, 2026 Ionis Pharmaceuticals and Roche announced positive prespecified interim results from the Phase 3 IMAgINATION study… Sep 23, 2026 On September 4, 2026, Ionis Pharmaceuticals announced that its partner Novartis reported the pelacarsen Phase 3… Sep 4, 2026 On September 3, 2026, the U.S. FDA approved ZANVASTRO (zilganersen) for the treatment of Alexander disease in… Sep 4, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
